Publications

Key publications

ESC 2023

This review will discuss the roles of cardiac non-myocytes and their dynamic intercellular interactions in the pathogenesis of diabetic cardiomyopathy.

BJP 2023

This review addresses the observed anti-fibrotic effects of newer glucose-lowering therapies and traditional cardiovascular disease treatments, in the diabetic myocardium (from preclinical and clinical contexts).

CellPress 2022

Experts in the cardiovascular field reflect on some of the global challenges and opportunities in translating basic and preclinical research discoveries into new treatments.

Publication highlights (Selected from 90 in the last 10 years)

  • Sharma A, Wood S, Bell JS, De Blasio MJ, Ilomäki J, Ritchie RH. (2023). Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: A population-based cohort study. The Lancet Regional Health-Western Pacific 33:100692. Published online January 30, 2023 DOI: https://doi.org/10.1016/j.lanwpc.2023.100692.
  • Cohen CD*, De Blasio MJ*, Farrugia GE, Dona MSI, Hsu I, Prakoso D, Kiriazis H, Krstevski C, Nash DM, Li M, Gaynor TL, Deo M, Drummond GR, Ritchie RH#, Pinto AR#. (2023). Mapping the Cellular and Molecular Landscape of the Diabetic Myocardium: Focus on Cardiac Non-Myocytes in a Murine Model of Type-2 Diabetes. iScience 2023 Aug 28;26(10):107759. doi: 10.1016/j.isci.2023.107759. JOINT SENIOR AND CORRESPONDING AUTHOR
  • Sharma A, De Blasio MJ, Ritchie RH. (2023). Current challenges in the treatment of cardiac fibrosis: recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR Review 33". British Journal of Pharmacology 180(22):2916-2933.
  • Yi XY, Tran E, Odiba JO, Qin CX#, Ritchie RH#, Baell JB#. (2023) The formyl peptide receptors FPR1 and FPR2 as a target for inflammatory disorders: recent advances in the development of small-molecule agonists. European Journal of Medicinal Chemistry (in press, accepted 20-11-23). JOINT CORRESPONDING AND SENIOR AUTHOR
  • Prakoso D, Lim SY, Erickson JR, Wallace RS, Lees JG, Tate M, Kiriazis H, Donner DG, Henstridge DC, Davey JR, Qian HW, Deo M, Parry LJ, Davidoff AJ, Gregorevic P, Chatham JC, De Blasio MJ*, Ritchie RH*. (2022). Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. Cardiovasc Res 118: 212-225.
  • Velagic A, Li JC, Qin CX, Li M, Deo M, Marshall SA, Anderson D, Woodman OL, Horowitz JD, Kemp-Harper BK, Ritchie RH. (2022). Cardioprotective Actions of Nitroxyl Donor Angeli's Salt are Preserved in the Diabetic Heart and Vasculature in the Face of Nitric Oxide Resistance. British Journal of Pharmacology 179(16):4117-4135.
  • Prakoso D, Tate M, De Blasio MJ, Ritchie RH. (2022). Current Landscape of Pre-Clinical Models of Diabetic Cardiomyopathy. Trends in Pharmacological Sciences 43(11):940-956.
  • Qin CQ*, Norling LV*, Vecchio EA, Brennan EP, May LTM, Wootten D, Godson C, Perretti M#, Ritchie RH#. (2022). Invited Review: Formyl Peptide Receptor 2: Nomenclature, Structure, Signalling and Translational Perspectives: IUPHAR Review 35 British Journal of Pharmacology 179: 4617-4639.
  • Sharma A, Choi J, Stefanovic N, Al Sharea A, Simpson D, Mukhamedova N, Jandeleit-Dahm K, Murphy AJ, Sviridov D, Vince JE, Ritchie RH, de Haan JB. (2021). Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis. Diabetes 70 (3), 772-787.
  • Figtree GA, Broadfoot K, Casadei B, Califf R, Crea F, Drummond GR, Freedman JE, Guzik T, Harrison D, Hausenloy DJ, Hill JA, Januzzi J, Kingwell BA, Lam CSP, MacRae CA, Misselwitz F, Miura T, Ritchie RH, Tomaszewski M, Wu JC, Xiao J, Zannad F. (2021). A call to action for new global approaches to cardiovascular disease drug solutions. European Heart Journal 42(15):1464-1475. doi:10.1093/eurheartj/ehab068 (co-publication in Circulation).
  • Cohen CD, De Blasio MJ, Lee MKS, Farrugia GE, Prakoso D, Krstevski C, Deo M, Donner DG, Kiriazis H, Flynn MC, Gaynor TL, Murphy AJ, Drummond GR, Pinto AR*, Ritchie RH*. (2021). Diastolic dysfunction in a pre-clinical model of diabetes is associated with changes in the cardiac non-myocyte cellular composition. Cardiovascular Diabetology 20 (1): 1-12; doi.org/10.1186/s12933-021-01303-9.
  • Qin CX#, Anthonisz J*, Leo CH*, Kahlberg N*, Velagic A, Li M, Jap E, Woodman OL, Parry LJ, Horowitz JD, Kemp-Harper BK, Ritchie RH#. (2020). NO resistance, induced in the myocardium by diabetes, is circumvented by the NO redox sibling, nitroxyl. Antiox Redox Signal 32(1):60-77.
  • Prakoso D*, De Blasio MJ*, Tate M, Kiriazis H, Donner DG, Qian HW, Nash D, Deo M, Weeks KL, Parry LJ, Gregorevic P, McMullen JR#, Ritchie RH#. (2020). Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes. Am J Physiol 318: H840-H852.
  • Ritchie RH, ED Abel. (2020). Obesity, Metabolic Syndrome, and CVD Compendium. Invited Review: Basic mechanisms of diabetic heart disease. Circulation Research 126: 1501-1525.
  • Qin CX, Rosli S, Deo M, Cao N, Walsh J, Tate M, Alexander AM, Donner D, Horlock D, Li R, Kiriazis H, Lee MKS, Bourke JE, Yang YH, Murphy AJ, Du XJ, Gao XM, Ritchie RH. (2019). Cardioprotective actions of the Annexin-A1 N-terminal peptide, Ac2-26, against myocardial infarction. Frontiers in Pharmacology 10:269. doi: 10.3389/fphar.2019.00269.
  • Deora GS*, Qin CX*, Vecchio EA, DeBono AJ, Priebbenow DL; Brady RM, Beveridge J, Teguh SC, Deo M, May LT, Krippner G, Ritchie RH#, Baell JB#. (2019). Substituted pyridazin-3(2H)-ones as highly potent and biased formyl peptide receptor agonists. Journal of Medicinal Chemistry 62(10): 5242-5248. JOINT SENIOR AUTHOR.
  • Tate M, Higgins GC, De Blasio MJ, Lindblom R, Prakoso D, Deo M, Kiriazis H, Ramm G, Baeza-Garza CD, Caldwell ST, Hartley RC, Krieg T, Murphy MP, Coughlan MT#, Ritchie RH#. (2019). The mitochondria-targeted methylglyoxal sequestering compound, MitoGamide, is cardioprotective in the diabetic heart. Cardiovasc Drugs Ther. 33(6):669-674 doi:10.1007/s10557-019-06914-9.
  • Marwick TH*; Ritchie RH*; Shaw JE, Kaye DM. (2018). Invited State-of-the-art Review. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol.71(3): 339-351. JOINT FIRST AUTHOR.
  • Qin CX*, May LT*, Sexton PM, DeBono AJ, Baell JB, Christopoulos A#, Ritchie RH#. (2018). Correspondence: Reply to 'Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury'. Nature Communications 9, Article 530, pages 1-4. doi:10.1038/s41467-017-02656-0.
  • Sharma A*, Tate M*, Mathew G, Vince J, Ritchie RH#, de Haan JB#. (2018). Invited review: Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Frontiers in Physiology 9, Article 114, pages 1-15. DOI: 10.3389/fphys.2018.00114. JOINT SENIOR AUTHOR.
  • Qin CX*, May LT*, Li R, Cao N, Rosli S, Deo M, Alexander AE, Horlock D, Bourke JE, Yang YH, Stewart AG, Kaye DM, Du XJ, Sexton PM, Christopoulos A, Gao XM#, Ritchie RH#. (2017). Small-molecule-biased formyl peptide receptor agonist compound17b protects against myocardial ischaemia-reperfusion injury in mice. Nature Communications 8, 14232, pages 1-13, doi: 10.1038/ncomms14232..
  • Prakoso D*, De Blasio MJ*, Qin CX, Rosli S, Kiriazis H, Qian HW, Du XJ, Weeks KL, Gregorevic P, McMullen JR#, Ritchie RH#. (2017). Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clinical Science 131: 1345-1360.
  • Tate M, Deo M, Cao AH, Hood SG, Huynh K, Kiriazis H, Du XJ, Julius TL, Figtree GA, Dusting GJ, Kaye DM, Ritchie RH. Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat. (2017). Diabetes & Vascular Disease Research 14(5): 423-433.
  • Qin CX, Finlayson SB, Al-Sharea A, Tate M, De Blasio MJ, Deo M, Rosli S, Prakoso D, Thomas CJ, Kiriazis H, Gould E, Yang YH, Morand EF, Perretti M, Murphy AJ, Du XJ, Gao XM#, Ritchie RH#. (2017). Endogenous annexin-A1 regulates haematopoietic stem cell mobilization and inflammatory response post myocardial infarction in mice in vivo. Scientific Reports 7: Article 16615, pages 1-14. Author correction (spelling of an author surname) 8: Article 7185.
  • Bowden MA*, Tesch GH*, Julius TL, Rosli S, Love JE, Ritchie RH. (2015). Earlier onset of diabesity-induced adverse cardiac remodeling in female compared to male mice. Obesity 23:1166-1177.
  • Cao N, Wong YG, Rosli S, Kiriazis H, Huynh K, Qin C, Du XJ, Kemp-Harper BK, Ritchie RH. (2015). Chronic administration of the nitroxyl donor 1-nitrosocyclohexyl acetate limits left ventricular diastolic dysfunction in a mouse model of diabetes in vivo. Circ Heart Fail 8:572-581.
  • De Blasio MJ*, Huynh K*, Qin CX, Rosli S, Kiriazis H, Ayer A, Cemerlang, Stocker R, Du XJ, McMullen JR#, Ritchie RH#. (2015). Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110α) signalling. Free Rad Biol Med 87:137-147.
  • Kemp-Harper BK, Horowitz JD, Ritchie RH. (2016). Invited Leading Article: Therapeutic potential of nitroxyl (HNO) donors in the management of acute decompensated heart failure (ADHF). Drugs 76(14): 1321-1412.
  • Huynh K, Bernardo BC, McMullen JR*, Ritchie RH*. Invited review: Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. (2014). Pharmacol Ther 142: 375-415.
  • Qin CX, Yang YH*, May LT*, Gao XM, Stewart A, Tu Y Woodman OL, Ritchie RH. (2014). Invited review: Cardioprotective potential of annexin-A1 mimetics in myocardial infarction. Pharmacol Ther 148:47-65.

A full list of her publications can be found here. Rebecca Ritchie‬ - Google Scholar‬‬‬‬‬

Publication list

Learn more